Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials

摘要

Schematic summarising the potential direct and indirect mechanisms of cardiovascular benefits associated with SGLT2 inhibitor use. BP blood pressure, CV cardiovascular, HbA1c glycated haemoglobin, Na/H sodium/hydrogen [17–25]